Alunbrig can be used as a second-line treatment for patients with anaplastic lymphoma kinase-postive metastastic non-small cell lung cancer who are already taking Pfizer’s drug crizotinib — the standard treatment for the disease.
Takeda gained rights to Alunbrig through its $5.2 billion acquisition of Ariad Pharmaceuticals in February.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.